Charles River (CRL) Extends Gene Therapy Offering With New Pact
https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549
Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
0
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
https://www.zacks.com/stock/news/2242295/revvity-s-rvty-new-launch-to-boost-newborn-sequencing-research?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242295
Mar 18, 2024 - Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
0
Labcorp (LH) Presents New Research on Precision Diagnostics
https://www.zacks.com/stock/news/2242254/labcorp-lh-presents-new-research-on-precision-diagnostics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242254
Mar 18, 2024 - Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
0
Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
https://www.zacks.com/stock/news/2243024/inspira-technologies-iinn-strives-to-get-amar-nod-for-art100?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243024
Mar 19, 2024 - The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
0
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
https://www.zacks.com/stock/news/2242630/here-s-why-you-should-retain-tandem-diabetes-tndm-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242630
Mar 19, 2024 - Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
0
Here's Why Investors Should Retain Abbott (ABT) Stock Now
https://www.zacks.com/stock/news/2243034/here-s-why-investors-should-retain-abbott-abt-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2243034
Mar 19, 2024 - Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
0
Here's Why You Should Retain HealthEquity (HQY) Stock Now
https://www.zacks.com/stock/news/2242869/here-s-why-you-should-retain-healthequity-hqy-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242869
Mar 19, 2024 - HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
0
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
https://www.zacks.com/stock/news/2243528/here-s-why-you-should-hold-surmodics-srdx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2243528
Mar 20, 2024 - Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
0
Here's Why You Should Retain Nevro (NVRO) Stock for Now
https://www.zacks.com/stock/news/2244409/here-s-why-you-should-retain-nevro-nvro-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2244409
Mar 21, 2024 - Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
0
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
https://www.zacks.com/stock/news/2244193/reasons-to-add-stryker-syk-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2244193
Mar 21, 2024 - Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
0